397 related articles for article (PubMed ID: 25255388)
1. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Xie Y; Xu D; Huang B; Ma X; Qi W; Shi F; Liu X; Zhang Y; Xu W
J Med Chem; 2014 Oct; 57(20):8445-58. PubMed ID: 25255388
[TBL] [Abstract][Full Text] [Related]
2. Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.
Ju H; Zhang J; Sun Z; Huang Z; Qi W; Huang B; Zhan P; Liu X
Eur J Med Chem; 2018 Feb; 146():220-231. PubMed ID: 29407952
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
Zhang H; Wang K; Zhu H; Zhao X; Zhao H; Lei Z; Chen B; Yang F; Liu K; Zhang K; Wang J; Tian Y
Eur J Med Chem; 2020 Aug; 200():112423. PubMed ID: 32512482
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of NH
Wang K; Yang F; Wang L; Liu K; Sun L; Lin B; Hu Y; Wang B; Cheng M; Tian Y
Eur J Med Chem; 2017 Dec; 141():648-656. PubMed ID: 29107426
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
Jia R; Zhang J; Bertagnin C; Cherukupalli S; Ai W; Ding X; Li Z; Zhang J; Ju H; Ma X; Loregian A; Huang B; Zhan P; Liu X
Eur J Med Chem; 2021 Feb; 212():113097. PubMed ID: 33385836
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors.
Jia R; Zhang J; Ai W; Ding X; Desta S; Sun L; Sun Z; Ma X; Li Z; Wang D; Huang B; Zhan P; Liu X
Eur J Med Chem; 2019 Sep; 178():64-80. PubMed ID: 31176096
[TBL] [Abstract][Full Text] [Related]
7. Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.
Zhao H; Jiang S; Ye Z; Zhu H; Hu B; Meng P; Hu Y; Zhang H; Wang K; Wang J; Tian Y
Eur J Med Chem; 2021 Oct; 221():113567. PubMed ID: 34082224
[TBL] [Abstract][Full Text] [Related]
8. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Rungrotmongkol T; Frecer V; De-Eknamkul W; Hannongbua S; Miertus S
Antiviral Res; 2009 Apr; 82(1):51-8. PubMed ID: 19428595
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of
Hu Y; Chen B; Lei Z; Zhao H; Zhu H; Quan P; Tian Y
Molecules; 2019 Jun; 24(11):. PubMed ID: 31185617
[TBL] [Abstract][Full Text] [Related]
10. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
Singh A; Soliman ME
Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
[TBL] [Abstract][Full Text] [Related]
11. Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.
Li Z; Meng Y; Xu S; Shen W; Meng Z; Wang Z; Ding G; Huang W; Xiao W; Xu J
Bioorg Med Chem; 2017 May; 25(10):2772-2781. PubMed ID: 28385598
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
Wang Z; Cheng LP; Zhang XH; Pang W; Li L; Zhao JL
Bioorg Med Chem Lett; 2017 Dec; 27(24):5429-5435. PubMed ID: 29141777
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
Ai W; Zhang J; Zalloum WA; Jia R; Cherukupalli S; Ding X; Sun Z; Sun L; Jiang X; Ma X; Li Z; Wang D; Huang B; Zhan P; Liu X
Eur J Med Chem; 2020 Apr; 191():112147. PubMed ID: 32092589
[TBL] [Abstract][Full Text] [Related]
14. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
[No Abstract] [Full Text] [Related]
15. Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
Wang K; Lei Z; Zhao L; Chen B; Yang F; Liu K; Zhu H; Zhao H; Cao R; Zhang K; Tian Y
Eur J Med Chem; 2020 Jan; 185():111841. PubMed ID: 31708183
[TBL] [Abstract][Full Text] [Related]
16. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Mitrasinovic PM
Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity.
Shie JJ; Fang JM; Wang SY; Tsai KC; Cheng YS; Yang AS; Hsiao SC; Su CY; Wong CH
J Am Chem Soc; 2007 Oct; 129(39):11892-3. PubMed ID: 17850083
[No Abstract] [Full Text] [Related]
18. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.
Albohy A; Mohan S; Zheng RB; Pinto BM; Cairo CW
Bioorg Med Chem; 2011 May; 19(9):2817-22. PubMed ID: 21489803
[TBL] [Abstract][Full Text] [Related]
19. The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors.
Lin X; Qin-Hua C; Peng L; Chun-Lei L; Guang-De Y
Chem Biol Drug Des; 2018 Jan; 91(1):105-115. PubMed ID: 28646621
[TBL] [Abstract][Full Text] [Related]
20. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
Park JW; Jo WH
J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
